Joseph Foley to Drug Discovery
This is a "connection" page, showing publications Joseph Foley has written about Drug Discovery.
Connection Strength
0.063
-
Yonchuk JG, Foley JP, Bolognese BJ, Logan G, Wixted WE, Kou JP, Chalupowicz DG, Feldser HG, Sanchez Y, Nie H, Callahan JF, Kerns JK, Podolin PL. Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress. J Pharmacol Exp Ther. 2017 10; 363(1):114-125.
Score: 0.033
-
Davies TG, Wixted WE, Coyle JE, Griffiths-Jones C, Hearn K, McMenamin R, Norton D, Rich SJ, Richardson C, Saxty G, Willems HM, Woolford AJ, Cottom JE, Kou JP, Yonchuk JG, Feldser HG, Sanchez Y, Foley JP, Bolognese BJ, Logan G, Podolin PL, Yan H, Callahan JF, Heightman TD, Kerns JK. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery. J Med Chem. 2016 04 28; 59(8):3991-4006.
Score: 0.030